FUSE Health vs. GNC: Prescription Program Comparison
Why peptides over the counter don't compete with prescription programs: the regulatory boundary, revenue model gap, and what each model is actually built for.
| Features And Capabilities | Fuse | GNC |
|---|---|---|
| Over-the-Counter Supplement Sales | yes | no |
| Prescription Clinical Workflows | yes | no |
| GLP-1 and Peptide Prescription Routing | yes | no |
| White Label Operator Storefront | yes | no |
| LegitScript Certified | yes | no |
| Recurring Subscription Revenue | yes | no |
| LegitScript Certified | yes | no |
| LegitScript Certified | yes | no |
GNC Sells Supplements. FUSE Builds Prescription Revenue Channels.
GNC sells peptides and supplements over the counter. Prescription GLP-1 and clinical peptide programs operate in a different category that requires provider oversight, compliant intake, and pharmacy routing. FUSE gives operators the infrastructure to build and scale those programs alongside their existing supplement business. Prescription peptide programs typically generate higher revenue per patient than supplement purchases because of the clinical component. Margin depends on program pricing and platform fee structure — both of which operators confirm before launching. Supplement customers who convert to a prescription peptide program have a documented interest in the clinical category and convert at significantly higher rates than cold audiences.
Prescription-grade infrastructure
FUSE includes provider networks, clinical intake, and pharmacy routing that supplement retail channels cannot provide. Every clinical touchpoint is compliant — prescribing workflows, state licensing logic, pharmacy routing, and BAA coverage.
Operator brand stays front
Every patient touchpoint runs under your brand while FUSE handles the clinical and compliance layer behind the scenes. Supplement customers who convert to clinical programs see one brand, not a FUSE-branded experience.
From supplements to a full revenue channel
Supplement operators with existing audiences can add a prescription digital health program without building clinical infrastructure from scratch. The supplement channel and clinical channel are complementary — customers in both channels have higher LTV than customers in either channel independently
Peptides Sold Over the Counter vs Prescription Clinical Programs
The regulatory difference is fundamental. OTC supplement peptides make no prescription claims and are sold under DSHEA. Prescription peptide programs require provider oversight, a clinical intake workflow that screens for contraindications, and pharmacy-grade fulfillment through a licensed compounding pharmacy. FUSE structures the prescription side — LegitScript certification, BAA coverage, state licensing logic, and compounding pharmacy routing are all pre-configured.
Compliance is built in
LegitScript certification, BAA coverage, and state licensing logic are pre-configured in FUSE. Operators do not build compliance systems — they configure a program and launch. Supplement retail compliance does not cover the prescribing workflow, patient data handling, or clinical documentation that prescription programs require.
Recurring revenue model
Subscription and refill logic converts one-time patients into a predictable monthly revenue stream. Prescription peptide programs on 90-day protocols create strong enrollment commitment and significantly higher retention than open-ended supplement subscriptions.
A Fundamentally Different Scheduling Experience.
| With FUSE | With GNC | |
|---|---|---|
| Revenue model | FUSE Health operators run prescription programs with recurring subscription revenue built into the patient journey from the first interaction. Programs compound over time. | GNC operates a retail supplement model. Recurring revenue from prescription programs requires a separate digital health infrastructure layer that GNC does not provide. |
| Clinical access | FUSE provides pre-configured provider networks so operators do not build clinical staffing from scratch. Licensed providers review patients across multiple states | Retail supplement channels cannot provide the licensed provider oversight required for prescription GLP-1 or clinical peptide programs. This is a regulatory boundary, not a capability gap. |
| Compliance structure | FUSE Health is LegitScript certified and includes BAA coverage and audit-ready logging. Prescription program compliance is built into the platform, not bolted on. | Supplement retail compliance covers product labeling and DSHEA requirements. It does not cover the prescribing workflow, patient health data, or clinical documentation required for digital health programs. |
| Launch speed | FUSE Health operators configure and launch in days because clinical infrastructure already exists. Provider networks, pharmacy routing, and compliance are pre-built. | Building a prescription digital health program from scratch without infrastructure takes 12 to 18 months before the first patient can be served compliantly. |
Daniel is a two-time founder who has scaled service businesses across major U.S. markets. A Y Combinator competition winner, he focuses on removing operational and regulatory barriers so operators can build and scale modern healthcare businesses.
- Background
- Startup Operations & Service Systems
- Experience
- 2x Founder, Multi-Market U.S. Scaling
- Qualifications
- Healthtech Market Expertise & Operational Scaling
- Key Achievement
- Scaled Premier Staff & Eventstaff across major U.S. markets